XUND, a Vienna-based HealthTech scaleup which specialises in building Software as a Medical Device (SaMD), has closed a €6 million pre-Series A funding round. The investment round was led by Lead Ventures and joined by J&T Ventures, with continued support from existing investors MassMutual Ventures, tba network, and LANA Ventures. XUND shared the news on their website.
About XUND
-
XUND, founded in 2018 by Lukas Seper, Tamás Petrovics and Zoltán Tarabó, the Vienna-based healthtech scale-up specializes in developing Software as a Medical Device (SaMD), enabling digital interactions from prevention to diagnosis.
-
With the vision of bringing clarity to the most important decisions in healthcare, XUND’s products are already used by insurers, hospitals, and pharmaceutical companies as the first digital point of contact.
“Our investment in XUND is driven by the thesis that AI-powered SaMD solutions will be the foundation of a more efficient, accessible, and data-driven healthcare system. What sets XUND apart is not only its world-class technology and the trust it has earned from some of the biggest names in healthcare but also the strength of its founding team and their bold vision,” says David Polach, Partner at J&T Ventures.
Investment details
The round was led by Lead Ventures and joined by J&T Ventures, with continued support from existing investors MassMutual Ventures, tba network, and LANA Ventures.
-
Budapest-based Lead Ventures partners with startups that have demonstrated market validation and need capital to scale. With a focus on founders from the CEE region and the Baltics, it invests in high-potential B2B software companies across various industries, providing funding and strategic support to help them expand on international markets. The company invested in Hungarian Parkl and Lithuanian RedTrack.
-
J&T Ventures is a Prague based VC firm managing over €80 million across three funds and invests up to €3 million in early and growth-stage technology companies across Central and South-Eastern Europe, focusing on sectors with strong innovation potential.
The round will help to accelerate the company’s xpansion in DACH and the UK, leveraging its MDR-certified technology to enable digital interactions from prevention to diagnosis.
